Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 204.08M P/E - EPS this Y 40.60% Ern Qtrly Grth -
Income -139.77M Forward P/E -2.01 EPS next Y 8.30% 50D Avg Chg -8.00%
Sales 145.87M PEG 0.03 EPS past 5Y - 200D Avg Chg -46.00%
Dividend N/A Price/Book N/A EPS next 5Y -30.30% 52W High Chg -70.00%
Recommedations 1.90 Quick Ratio 3.97 Shares Outstanding 114.53M 52W Low Chg 24.00%
Insider Own 4.95% ROA -28.91% Shares Float 104.89M Beta -0.19
Inst Own 69.04% ROE - Shares Shorted/Prior 18.90M/17.95M Price 1.79
Gross Margin 108.94% Profit Margin -95.82% Avg. Volume 3,435,614 Target Price 6.14
Oper. Margin -86.81% Earnings Date Feb 29 Volume 2,225,002 Change -0.56%
About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc. News
02/22/24 Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
02/19/24 Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
02/15/24 Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02/14/24 Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
02/07/24 Karyopharm Therapeutics (NASDAQ:KPTI) adds US$104m to market cap in the past 7 days, though investors from three years ago are still down 90%
02/01/24 Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/08/24 Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
01/03/24 Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
12/10/23 Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
12/06/23 Great week for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) institutional investors after losing 84% over the previous year
11/08/23 Karyopharm to Participate at Upcoming Investor Conferences
11/06/23 Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
11/03/23 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2023 Earnings Call Transcript
11/02/23 Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript
11/02/23 Karyopharm Therapeutics Inc (KPTI) Reports Q3 2023 Earnings, Total Revenue of $36.0 Million
11/02/23 Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
11/02/23 Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
10/30/23 Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
06:00 AM Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
06:00 AM Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
KPTI Chatroom

User Image longrigger52 Posted - 19 hours ago

$KPTI FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy in Endometrial Cancer. their phase 3 was pfs 13 months...better than chemo alone but not as good as seli. but again will be beat to market. Would an approval like this lessen the need for fda to make conditional approval upon full enrollment?????

User Image Gius_me Posted - 1 day ago

$KPTI I was checking q3 cash and unaudited q4…192 vs 209…it seems we burnt only 17 mln, it could be not that bad. The main problem still remains the bond note 2025 and general cash on hand 🥹😫😞

User Image Germantrade1982 Posted - 1 day ago

$KPTI probably no price increase here in the near future.

User Image AlexPEC Posted - 1 day ago

$KPTI https://www.targetedonc.com/view/notable-outcomes-of-selinexor-based-triplet-therapy-addressed-in-rrmm

User Image Gius_me Posted - 2 days ago

$KPTI she is stuck in the downtrend line

User Image redog677 Posted - 2 days ago

$KPTI screenshot

User Image redog677 Posted - 2 days ago

$KPTI Looking at level 2 I see 90800 shares by arca for 1.22 bid. is that a big buy or seller? I thought it was big buyer. if so than why is it flashing red color? also isn't it suppose to make the price go up???

User Image longrigger52 Posted - 2 days ago

$KPTI I'll take it

User Image Notyouraverage_shark Posted - 2 days ago

$KPTI I’ll keep buying

User Image redog677 Posted - 2 days ago

$KPTI well we are at yesterday's high of 1.26. can we break through this? we will soon find out. I think so.

User Image Gius_me Posted - 2 days ago

$KPTI small sign of life 🥹🥹🥹

User Image TheRealStocksavior Posted - 2 days ago

$KPTI just keep loading!!

User Image Gius_me Posted - 2 days ago

$KPTI I hope in any small bounce today. I’m speechless 😶🥹😞😫

User Image okhello1 Posted - 3 days ago

$KPTI Come on go down to $0.80 again, I will buy a truck load.

User Image Honeysuckle4384 Posted - 3 days ago

$KPTI So what to make of the pricing and earnings delay. Price spike to $1.95 on 2/6 with 10x daily volume in first 2 hours and 5x rest of the day. What is the cause of this spike as it seems like a pretty big buyer was getting what they can. I didn't see a need to drive so hard and fast. Now 2 weeks later we have the earnings release date. I don't think they delayed unless something that was a notable catalyst. I can see them announcing earnings date only when material event is in place (BO or AA). I don't think they would have delayed if something was just possible. Had to be a little more firm than that

User Image ekpemofolo Posted - 3 days ago

$KPTI as for your daily dose of "positive morale", here it goes: whenever blob gets active on the board, it is the sign that a bottom is in. We love you blob.

User Image ekpemofolo Posted - 3 days ago

$KPTI wow what a deviation from the market, coinciding with the earnings date release. Terrible to watch, sure, but also strangely bullish imo. As far as I am concerned we are in an uptrend since we had that instant drop to 75 cents some weeks ago. Sharp pullback is the way the beast summons energy to spring forward. Thursday morning earnings (positive choice of date/time) might be a turning point of some sort.

User Image Gius_me Posted - 3 days ago

$KPTI WTF 😞😩🫤🤦‍♂️ we have er, at least they must say something

User Image Notyouraverage_shark Posted - 3 days ago

$KPTI not looking good lmao I’ll hold hope

User Image longrigger52 Posted - 3 days ago

$KPTI timbbbbber........180 days right ????

User Image PrettyBlob Posted - 3 days ago

$KPTI What’s a drop of 10% against XBI in a day? NBD. Back to the KPTI of old. on the other hand, an interesting descending wedge forming. I’d say earnings would be the catalyst to break out the pattern to the upside, but let’s be honest - this management team isn’t going to bring anything remarkable to the table. Sell. The. Company. I’ll take $2 a share now 😂

User Image Gius_me Posted - 3 days ago

$KPTI however we are not so far from the first readout. Just wondering if h2 24 is July or December 😅

User Image Gius_me Posted - 3 days ago

$KPTI how much will we have in bank account right now? 170mln?

User Image celebratelife Posted - 3 days ago

$KPTI I am confident Mike Mason, Mike Mano, Richard Paulson, will further screw up. Just my hunch. Hoping for the best for shareholders but the gang that can't shoot straight is its own worst enemy. And short hedgies LOVE 'em.

User Image PrettyBlob Posted - 3 days ago

$KPTI Another day of slow bleed counter to both the broader market and sector. Presumably NASDAQ compliance will become an issue again after lackluster earnings release next week, which absent any material guidance on items of importance pertaining to this company as a going concern shorts will again pounce. Leave it to this harebrained mgmt team to fail to capitalize on the spike…

User Image steven1x Posted - 3 days ago

$KPTI https://app.webinar.net/R0YZl5XgxWk

User Image Stock_Titan Posted - 3 days ago

$KPTI Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 https://www.stocktitan.net/news/KPTI/karyopharm-to-report-fourth-quarter-and-full-year-2023-financial-mwwt4p3ck5x1.html

User Image Giggtitties Posted - 4 days ago

$KPTI Do not think there would be a significant pump here soon unless management could somehow guarantee that debt would not be restructured at the expense of shareholders. I still believe in the science but we shareholders have underestimated the time required for data to mature enough to become an attractive investment hence suffered from the decrease stock price. Just speculation.

User Image ekpemofolo Posted - 4 days ago

$KPTI I am in the mood for some good old pumping. Let's fantasize about buyouts. Here is a fun fact: Mikael Dolsten is the chief scientific officer of Pfizer since 2010. Between 2015-2020 he was on the board of Karyopharm. A few months after Xpovio is approved by FDA, he leaves the BoD. A conspiracy theory could have been that Pfizer had its eye on Karyo. Is there anyone around from 4 years ago? Blob? Was there any mention in particular about PFE-KPTI connection? If so, is that flame still burning? Come on, get those fingers typing!

User Image ScottyDoesntKnowMeSon Posted - 4 days ago

$KPTI did they mention how long of a delay earnings would be?

Analyst Ratings
Piper Sandler Overweight Nov 3, 23
RBC Capital Outperform Nov 3, 23
Morgan Stanley Equal-Weight Aug 7, 23
Piper Sandler Overweight Aug 3, 23
RBC Capital Outperform Aug 3, 23
HC Wainwright & Co. Buy Aug 3, 23
Wedbush Neutral Jul 26, 23
HC Wainwright & Co. Buy Jul 26, 23
HC Wainwright & Co. Buy Jul 18, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Paulson Richard A. President and CEO President and CEO Jan 04 Sell 0.82 4,114 3,373 783,465 01/08/24
Paulson Richard A. President and CEO President and CEO Dec 04 Sell 0.79 3,622 2,861 787,579 12/05/23
Paulson Richard A. President and CEO President and CEO Nov 06 Sell 0.9203 3,606 3,319 791,201 11/07/23
Paulson Richard A. President and CEO President and CEO Oct 04 Sell 1.27 3,589 4,558 794,807 10/05/23
BOHLIN GAREN G Director Director Sep 12 Buy 1.215 41,140 49,985 45,140 09/12/23
Paulson Richard A. President and CEO President and CEO Aug 07 Sell 1.72 3,722 6,402 802,018 08/08/23
Poulton Stuart EVP, Chief Developme.. EVP, Chief Development Officer Jul 28 Sell 1.70 2,845 4,836 156,286 08/01/23
Paulson Richard A. President and CEO President and CEO Jul 05 Sell 1.72 3,538 6,085 805,740 07/06/23
Rangwala Reshma EVP & Chief Medical.. EVP & Chief Medical Officer Apr 20 Sell 4.04 6,770 27,351 158,230 04/24/23
Paulson Richard A. President and CEO President and CEO Apr 04 Sell 3.97 3,497 13,883 816,619 04/05/23
Mason Michael EVP, CFO & Treasurer EVP, CFO & Treasurer Feb 28 Sell 3.03 11,205 33,951 245,361 03/02/23
Paulson Richard A. President and CEO President and CEO Feb 28 Sell 3.03 33,033 100,090 823,622 03/02/23
Paulson Richard A. President and CEO President and CEO Dec 05 Sell 5.17 3,490 18,043 612,527 12/06/22
Paulson Richard A. President and CEO President and CEO Nov 04 Sell 4.54 3,493 15,858 616,017 11/08/22
Paulson Richard A. President and CEO President and CEO Sep 08 Sell 5.24 3,479 18,230 622,998 09/09/22
Greene Barry E Director Director Aug 11 Option 1.485 7,576 11,250 13,606 08/15/22
Cheng Sohanya Roshan Chief Commercial Off.. Chief Commercial Officer Jun 13 Sell 5.27 1,551 8,174 89,949 06/14/22
PAKIANATHAN DEEPIKA Director Director Jun 08 Sell 6.23 538,784 3,356,624 16,673 06/10/22
Paulson Richard A. President and CEO President and CEO Jun 07 Sell 5.7602 2,542 14,642 630,906 06/08/22
Mason Michael EVP, CFO, Treasurer EVP, CFO, Treasurer Jun 03 Sell 6.05 601 3,636 138,509 06/06/22
Shacham Sharon Chief Scientific Off.. Chief Scientific Officer Feb 28 Sell 10.24 12,452 127,508 713,757 03/02/22
Kauffman Michael Director Director Feb 28 Sell 10.24 12,452 127,508 898,131 03/02/22
Kauffman Michael Director Director Feb 17 Sell 12.12 18,167 220,184 904,357 02/22/22
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 07 Sell 9.862 1,704 16,805 130,756 02/09/22
Frenkel Ran EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer Feb 07 Sell 9.862 1,991 19,635 104,632 02/09/22
Mason Michael EVP, CFO & Treasurer EVP, CFO & Treasurer Feb 07 Sell 9.862 3,947 38,925 53,308 02/09/22
Kauffman Michael Director Director Feb 07 Sell 9.86 13,471 132,824 913,445 02/09/22
Shacham Sharon Chief Scientific Off.. Chief Scientific Officer Feb 07 Sell 9.86 13,471 132,824 708,062 02/09/22
Shacham Sharon President & CSO President & CSO Feb 22 Sell 14.83 18,990 281,622 575,126 02/22/21
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 17 Sell 15.52 1,748 27,129 48,127 02/17/21
Frenkel Ran EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer Feb 17 Sell 15.52 2,046 31,754 39,338 02/17/21
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Feb 17 Sell 15.52 13,243 205,531 764,147 02/17/21
Mirza Mansoor Raza Director Director Dec 22 Sell 18 5,000 90,000 12/22/20
Mirza Mansoor Raza Director Director Dec 22 Option 5.43 5,000 27,150 5,000 12/22/20
Lewis Tanya EVP,Chief Reg.&Quali.. EVP,Chief Reg.&Quality Officer Nov 04 Sell 15.58 226 3,521 539 11/04/20
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Nov 04 Sell 19.46 589 11,462 43,229 11/04/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Oct 14 Option 9.8 39,271 384,856 5,370 10/14/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Oct 14 Sell 17.03 39,271 668,785 4,649 10/14/20
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Oct 14 Option 0.03 7,500 225 763,989 10/14/20
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Oct 14 Sell 14.89 7,500 111,675 756,489 10/14/20
Shacham Sharon President & CSO President & CSO Oct 14 Option 0.03 7,500 225 763,989 10/14/20
Shacham Sharon President & CSO President & CSO Oct 14 Sell 14.89 7,500 111,675 756,489 10/14/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Sep 10 Option 6.54 10,054 65,753 14,703 09/10/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Sep 10 Sell 14.98 10,054 150,609 4,649 09/10/20